Efficacy and safety of Pediatric Huanglong Granule in children with attention deficit hyperactivity disorder: study protocol for a randomized, double-blind, placebo-controlled, multicenter clinical trial

INTERVENTION: Treatment Group:Pediatric Huanglong Granule;Control Group:Pediatric Huanglong Granule Placebo; CONDITION: Attention deficit hyperactivity disorder PRIMARY OUTCOME: Attention Deficit and Hyperactivity Disorder‐RS‐IV‐Parent:Inv; SECONDARY OUTCOME: Weiss functional impairment rating scale, parent form;Clinical Global Impression?Severity scale;Clinical Global Impressions‐Improvement;TCM syndromes scale; INCLUSION CRITERIA: 1. Conform to the diagnostic criteria of ADHD (clinical diagnosis by doctors) in DSM‐5; 2. It conforms to the TCM syndrome differentiation standard of yin deficiency and yang hyperactivity syndrome 3. 6 years of age 14 years of age, regardless of gender 4. The total score of ADHD Rating Scale‐IV Parent Version, Investigator Administered (ADHD‐RS‐IV‐Parent: Inv) is >= 25 for males and >= 22 for females 5. CGI‐S score >= 4 6. Both parents (guardians) and patients agree to participate in the test, and both parents (guardians) or one party and the patient need to sign an informed consent form (patients younger than 8 years old do not need to sign an informed consent form, but only make an informed notification),